Tadalafil

Drugs

Volumn 63, Issue 20, 2003, Pages 2203-2212

  Curran, Monique P ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE; SILDENAFIL; TADALAFIL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CLINICAL TRIAL; DIABETES MELLITUS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MARKETING; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; HEADACHE; HUMAN; PENIS ERECTION; REVIEW; SEXUAL INTERCOURSE; SIDE EFFECT; TREATMENT OUTCOME;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; CARBOLINES; CLINICAL TRIALS; DIABETES COMPLICATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; TREATMENT OUTCOME;

EID: 0142105947     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363200-00004     Document Type: Review

References (31)

1. NIH Consensus Development Panel on Impotence. Impotence. JAMA 1993 Jul 7; 270: 83-90
2. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994 Jan; 151 (1): 54-61
3. Marumo K, Nakashima J, Murai M. Age-related prevalence of erectile dysfunction in Japan: assessment by the International Index of Erectile Function. Int J Urol 2001 Feb; 8 (2): 53-9
4. Blanker MH, Bosch JL, Groeneveld FP, et al. Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: prevalence, concern, and relation to sexual activity. Urology 2001 Apr; 57 (4): 763-8
5. Langtry HD, Markham A. Sildenafil; a review of its use in erectile dysfunction. Drugs 1999; 57: 967-87
6. Eardley I. New oral therapies for the treatment of erectile dysfunction. Br J Urol 1998 Jan; 81: 122-7
7. Truss MC, Stief CG. Phosphodiesterase inhibitors in the treatment of erectile dysfunction. Drugs Today 1998 Sep; 34: 805-12
8. Rotella DP. Phosphodiesterase type 5 inhibitors: discovery and therapeutic utility. Drugs Future 2001; 26 (2): 153-62
9. Angulo J, Gadau M, Fernandez A, et al. IC351 enhances nitric oxide-mediated relaxation of human arterial and trabecular penile smooth muscle [abstract no. 1133 plus poster]. Diabetologia 2001; 44 Suppl. 1: A295
10. Gbekor E, Bethell S, Fawcett L, et al. Phosphodiesterase 5 inhibitor profiles against all human phosphodiesterase families: implications for use as pharmacological tools [abstract no. 967]. J Urol 2002; 167 Suppl. 4: 246
11. Meuleman E, Lycklama NGL, Slob K, et al. Effects of IC351 on erectile response to visual sexual stimulation. J Urol 1999 Apr; 161 Suppl.: 212
12. Lilly ICOS Limited. Tadalafil (Cialis™): summary of product characteristics. London: Lilly ICOS Limited, 2003
13. Porst H, Padma-Natham H, Giuliano F, et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomised controlled study. Urology 2003; 62: 121-6
14. Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil in men with erectile dysfunction: results of integrated analysis. J Urol 2002; 168: 1332-6
15. Padma-Nathan H, Rosen RC, Shabsigh R, et al. Cialis™ (IC351) provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction. J Urol 2001 May; 165 Suppl.: 224
16. Hutter Jr AM, Kloner RA, Watkins VS, et al. Blood pressure and cardiovascular effects of tadalafil, a new PDE5 inhibitor [abstract no. P-302 plus poster]. Am J Hypertens 2002; 15 (Pt 2): 140
17. Patterson D, MacDonald TM, Effron MB, et al. Tadalafil does not affect time to ischemia during exercise stress testing in patients with coronary artery disease [abstract no. 1650]. Circulation 2002; 106 (19 Suppl. II): 330
18. Mitchell M, Sanderson B, Payne C, et al. Pharmacodynamic interaction between alcohol and tadalafil in healthy volunteers [abstract no. P-112]. Proceedings of the 5th Congress of the European Society for Sexual and Impotence Research; 2002 Dec 1-4; Hamburg
19. Kloner RA, Mitchell MI, Bedding A, et al. Pharmacodynamic interactions between tadalafil and nitrates compared with sildenafil [abstract no. 708]. J Urol 2002; 167 Suppl.: 176
20. Kloner R, Emmick J, Bedding A, et al. Pharmacodynamic interactions between tadalafil and nitrates [abstract no. 1051-30]. J Am Coll Cardiol 2002; 39 Suppl. A: 291A
21. Patterson B, Bedding A, Jewell H, et al. Dose-normalised pharmacokinetics of tadalafil administered as a single dose to healthy volunteers [abstract no. 600]. Eur Urol 2002; 41 Suppl. 1: 152
22. Porst H. IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res 2002 Feb; 14 Suppl. 1: S57-64
23. Patterson B, Bedding A, Jewell H, et al. The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351) [abstract plus poster]. Proceedings of the 4th Congress of the European Society for Sexual and Impotence Research; 2001 Sep 30-Oct 3; Rome
24. Sáenz de Tejada I, Anglin G, Knight JR, et al. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002; 25(12): 2159-64
25. Padma-Nathan H, McMurray JG, Pullman WE, et al. On-demand IC351 (Cialis™) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 2001 Feb; 13 (1): 2-9
26. Anglin G, Iglesias J, Toulouse K, et al. Efficacy and safety of IC351 treatment for erectile dysfunction [abstract no. B8]. Int J Impot Res 2000; 12 Suppl. 3: S75
27. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49 (6): 822-30
28. Nash DT. The safety and efficacy of tadalafil in elderly men with ED [abstract no. 48]. Am J Geriatr Cardiol 2003; 12 (2): 138-9
29. Montorsi F, Verheyden B, Junemann K-P, et al. Long-term safety experience with tadalafil [abstract no. 947]. J Urol 2003; 169 Suppl. 4: 245
30. Kloner RA, Watkins VS, Costigan TM, et al. Cardiovascular profile of tadalafil, a new PDE5 inhibitor [abstract no. 707]. J Urol 2002; 167 Suppl.: 176
31. Hellstrom W, Overstreet JW, Yu A, et al. Tadalafil has no effect on spermatogenesis or reproductive hormones [abstract no. 948]. 2003; 169 (4 Suppl.): 245